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Abstract Cardiacmuscle adapts to hemodynamic stress by
altering myocyte size and function, resulting in cardiac
hypertrophy. Alteration in myocyte calcium homeostasis is
known to be an initial signal in cardiac hypertrophy signal-
ing. Transient receptor potential melastatin 4 protein
(TRPM4) is a calcium-activated non-selective cation chan-
nel, which plays a role in regulating calcium influx and
calcium-dependent cell functions in many cell types
including cardiomyocytes. Selective deletion of TRPM4
from the heart muscle in mice resulted in an increased
hypertrophic growth after chronic angiotensin (AngII)
treatment, compared to WT mice. The enhanced hyper-
trophic response was also traceable by the increased
expression of hypertrophy-related genes like Rcan1, ANP,
and a-Actin. Intracellular calciummeasurements on isolated
ventricular myocytes showed significantly increased store-
operated calcium entry upon AngII treatment in myocytes
lacking the TRPM4 channel. Elevated intracellular calcium
is a key factor in the development of pathological cardiac
hypertrophy, leading to the activation of intracellular sig-
naling pathways. In agreement with this, we observed sig-
nificantly higher Rcan1 mRNA level, calcineurin enzyme
activity and protein level in lysates from TRPM4-deficient
mice heart compared to WT after AngII treatment. Collec-
tively, these observations are consistent with a model in
which TRPM4 is a regulator of calcium homeostasis in
cardiomyocytes after AngII stimulation. TRPM4 contributes
to the regulation of driving force for store-operated calcium
entry and thereby the activation of the calcineurin–NFAT
pathway and the development of pathological hypertrophy.
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Introduction
Cardiac hypertrophy is characterized by an increase in heart
mass and associated changes in the shape of the left ventricle
[13]. The defining signs of pathological cardiac hypertrophy
are an increase in cardiomyocyte size, enhanced protein
synthesis, and an increase in cardiac fibroblast proliferation
[9]. Pathological hypertrophy can be triggered by humoral
stimuli such as angiotensin II, or conditions such as hyper-
tension, valvular dysfunction and myocardial infarction [8].
In general, hypertrophic growth is considered as an adaptive
response to pathological stimuli, to preserve pump function
of the heart. However, prolonged hypertrophy is associated
with a significant increase in the risk for sudden death or
progression to heart failure. In the past decades, many
intracellular signaling pathways have been shown to be
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involved in hypertrophic response including MAPK, cal-
cineurin–NFAT, CaMKII–HDAC, PKC alpha, ERKs and
JNKs [14]. Although signal-transduction pathways are
inherently complex and abundant, one of the most common
initial events in the onset of hypertrophy is an alteration in
Ca2? homeostasis. Elevated systolic and/or diastolic [Ca2?]i
can activate intracellular cascades leading to hypertrophic
growth. Obviously, cardiomyocytes exhibit dramatic fluc-
tuations of [Ca2?]i during the cardiac cycle, making it dif-
ficult to explain how Ca2?-activated signaling proteins
function. One possibility is the presence of specialized pools
of Ca2? which are spatially separated from the bulk Ca2?.
However, the source of this subcellular Ca2? still remains
doubtful. Growing evidence points to voltage-gated Ca2?
channels, i.e., L-type, T-type [3, 23], as well as TRPC
channels [10, 33] as the source of this Ca2?. In addition,
recent studies also suggested store-operated calcium entry
(SOCE) as an important mechanism in cardiac hypertrophy
signaling [15, 16, 32].
The transient receptor potential (TRP) superfamily of
ion channels forms a large and diverse family of cation
channels related to the product of the trp gene in Droso-
phila. In the heart, the presence of several TRPs has been
reported, including TRPC1, TRPC3-7, TRPV1, TRPV2,
TRPV4, TRPM4, TRPM6 and TRPP2 [19]. TRPM4, a
member of the TRPM subfamily, is a calcium-activated
non-selective cation channel. The channel is equally per-
meable to Na? and K?, but impermeable to Ca2?. The
calcium sensitivity can be modulated by protein kinase C
(PKC)-mediated phosphorylation, cellular PIP2 levels and
by membrane depolarization [31]. In humans and also in
rodents, TRPM4 has been detected both in atria and ven-
tricles [39], and also in vascular endothelium and smooth
muscle [7]. Recently, we have shown that TRPM4 channel
activity can regulate cardiac contractility in the mouse
heart. The lack of the channel results in shortening of
action potential duration and an increased Ca2? current via
voltage-gated Ca2? channels, which becomes even more
prominent during beta-adrenergic stimulation in ventricular
myocytes [24, 36], and which is especially relevant during
heart failure [20]. A role for TRPM4 has been suggested in
several physiological and pathological processes in the
cardiovascular system [22]. TRPM4 is overexpressed in the
hypertrophied hearts of spontaneously hypertensive rats,
but the physiological function of TRPM4 in this process is
unclear [5]. Recently, mutations in the TRPM4 gene, which
are associated with Brugada syndrome, long QT syndrome
and cardiac conduction defects, such as Progressive
familiar heart block type I [21, 26, 34], have been reported.
Also, it was shown that TRPM4-deficient mice display
moderate hypertension, which is a result of the increased
level of catecholamines in blood plasma of TRPM4-defi-
cient mice compared to WT [25].
In the current study, we show that TRPM4 fine-tunes the
amount of Ca2? entry via store-operated Ca2? channels
into cardiomyocytes after chronic AngII stimulation,
thereby determining the degree of calcineurin–NFAT
activation, which is a signaling cascade that is both suffi-
cient and required for the hypertrophic response [28].
Results
Generation of cardiac-specific TRPM4 knockout
mouse
Considering that hypertension and increased plasma cate-
cholamine levels, which can influence the tendency to
develop hypertrophy, were recently reported in global
TRPM4-deficient mice [25], we have generated a cardiac-
specific TRPM4 knockout mouse line (Trpm4cKO), through
crossbreeding of Trpm4flox mice with MLC2a-Cre mice [40]
(Fig. 1a). This results in cardiac-specific deletion of exon 15
and 16 from the Trpm4 gene, which encode for the first
transmembrane domain of the TRPM4 protein [37].Western
blotting confirmed deletion of the TRPM4 protein from the
heart of Trpm4cKO mice (Fig. 1b). To compare blood pres-
sure in awake, freely moving WT and Trpm4cKO mice, we
implanted telemetric devices. Blood pressure and heart rate
as measured over the course of 2 weeks after transmitter
implantation were essentially identical in Trpm4cKO mice
andMLC2a-Cre-negative Trpm4flox/-mice (Supplementary
Figure 1).
TRPM4 deficiency in myocytes causes increased
cardiac hypertrophy after chronic angiotensin
treatment
In previous studies, we have shown by different approaches
that TRPM4 protein is expressed in mouse heart, both in
ventricles and atria, but absent inTRPM4knockoutmice [25].
Western blot analysis showedclear expression inhearts ofWT
and Cre- Trpm4flox/- mice, but TRPM4 was absent in the
heart of Cre? Trpm4flox/- mice (Trpm4cKO, Fig. 1b). To
evaluate the effect of TRPM4 on the development of cardiac
hypertrophy, we performed chronic angiotensin II (AngII)
infusion in WT and Trpm4cKO mice. AngII is a widely used
drug to induce cardiac hypertrophy experimentally [27, 38].
We have usedmini-osmotic pumps, implanted under the back
skin, to deliver 3 mg/kg/day AngII during 2 weeks. As a
negative control, we implanted pumps filled with saline in
both genotypes. To analyze the hypertrophic effect of AngII,
at the end of the experiment, the heart weight:body weight
(HW/BW)andheartweight:tibial length (HW/TL) ratioswere
compared. In the saline-treated groups, no differences were
observed between WT and Trpm4cKO mice. However, in the
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AngII-treated groups, Trpm4cKO mice displayed a significant
increase in HW/BW and HW/TL ratios, compared to WT
mice (Fig. 2a, b). To test age-related spontaneous develop-
ment of hypertrophy inTrpm4cKO andWTmice,wemeasured
HW/BW and HW/TL ratios in *1-year-old mice. We
detected no difference in heart weight or in body weight
between the two genotypes (Fig. 2c). To test whether the
presence of the Cre recombinase in the Trpm4cKO mice has
any effect on the AngII-induced hypertrophic response, we
performed AngII infusion experiments on Cre-positive and
Cre-negative Trpm4?/? mice. As shown in Supplementary
Figure 2, the presence of Cre recombinase had no significant
effect on HW/BW and HW/TL ratios after AngII treatment in
our experimental conditions. Finally, we tested whether the
AngII treatment had any effect on TRPM4 expression on the
WT heart. To this end, we performed TRPM4-specific qPCR
and Western blot (Fig. 2d, e), which showed no difference in
the amount of TRPM4 mRNA or protein level between con-
trol and AngII-treated WT mice.
Histological analysis of hypertrophied hearts
from WT and Trpm4cKO mice
To further evaluate the hypertrophic response, we performed
histological analysis of the cardiac muscle form saline- and
AngII-treated mice. Representative pictures from each group
Fig. 1 Generation of cardiac-
specific TRPM4 knockout mice
(Trpm4cKO). a Targeting of the
TRPM4 gene, as described
previously [40]. To obtain the
cardiac-specific knockout,
Trpm4flox/flox animals were
crossed with MLC2a-Cre mice.
See the text for more details.
b Representative Western blot
of protein fractions from the left
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are shown in Fig. 3a. The level of cardiac fibrosis was deter-
mined withMasson’s trichrome staining. Fibrosis was obvious
in the hearts after AngII application (Fig. 3b), but we did not
observe differences between the genotypes (Supplementary
Figure 3). Instead, the cross-sectional area of WT and Trp-
m4cKO myocytes were 193.2 ± 14 and 271.4 ± 12 lm2,
respectively, after AngII treatment (n = 150 cells from 3mice
for each genotype, p\0.05; Fig. 3c).
Expression of hypertrophy marker genes
To further investigate the altered hypertrophic response
in Trpm4cKO mice, we performed qPCR experiments to
evaluate the expression level of known cardiac
hypertrophy ‘‘marker’’ genes, i.e., a-actin, myosin
heavy chain beta (MYH7), atrial natriuretic peptide
(ANP), Rcan1 (a negative regulator of calcineurin of
which the transcription is highly dependent on cal-
cineurin–NFAT activation) and the a1H subunit of
voltage-gated T-type Ca2? channel (CACNA1H),
which is also known to be re-expressed upon cardiac
hypertrophy [3]. All these markers showed upregula-
tion after AngII treatment (Supplementary Figure 4),
but a specific stronger upregulation of a-actin, ANP
and Rcan1 was observed in Trpm4cKO compared to WT
(Fig. 3d).
Fig. 2 Trpm4cKO mice display
increased heart size compared to
WT upon AngII treatment.
a Heart weight/body weight
(HW/BW) and b heart weight/
tibial length (HW/TL) ratios of
WT and Trpm4cKO mice after
sham or Ang II (3 mg/kg/day
during 2 weeks via osmotic
pumps) treatment. At the time
of the experiment (8–12 weeks
of age), body weight was not
different between groups.
(mean ± SEM; WT sham:
n = 7; WT treated n = 10;
Trpm4cKO sham: n = 7;
Trpm4cKO n = 10; *p\ 0.05).
c Baseline hypertrophy as
developed with aging (1 year
old) (mean ± SEM; n = 5 for
each group). d TRPM4-specific
qPCR and Western blot
(e) show no difference in
TRPM4 mRNA and protein
expression level after AngII
treatment in WT mice (n = 4).
A cardiac muscle lysate from
Trpm4-/- mice was added to
underline the specificity of the
antibody (right panel, middle
lane)
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TRPM4 deficiency increases the hypertrophic
response to AngII of cultured neonatal myocytes
AngII application can have at least two distinct effects on the
cardiovascular system, vasoconstrictionand subsequentblood
pressure elevation, and a direct effect on cardiomyocytes via
Ang II receptor type 1 (AT1R). To investigate the direct cel-
lular effect of AngII, we used mouse neonatal ventricular
myocytes. Cells were isolated from 1- to 2-day-old pups. The
secondday after isolation, the culturemediumwas switched to
serum-free medium supplemented with 1 lmol/L AngII.
After 2 days incubation with AngII, the cell size was
determined. Since neonatal myocytes can have a different
gene expression profile compared to adult myocytes, we first
tested whether TRPM4 is expressed in WT neonatal cells.
Western blotting experiments showed a clear expression of
TRPM4 protein in WT and a complete absence in Trpm4-/-
neonatal hearts (Fig. 4a). Similar to our in vivo findings, there
was no significant difference between WT and TRPM4-defi-
cient cells in surface area under basal condition. However,
after 2 days of AngII treatment, the surface area of the WT
cells was 445.6 ± 17 lm2 compared to 564.2 ± 14 lm2 in
case of TRPM4-deficient cells (50–70 cells from 3 indepen-
dent preparations for each group, p\ 0.01) (Fig. 4b).
Fig. 3 Increased hypertrophic
phenotype in Trpm4cKO mice
compared to WT.
a Representative pictures from
WT and Trpm4cKO hearts, after
2 weeks of sham or AngII
treatment, as indicated.
b Representative pictures of
Masson’s trichrome-stained left
ventricular tissues of WT and
Trpm4cKO mice with or without
AngII treatment. Blue area
indicates fibrosis. Scale bar
50 lm. c Cross-sectional area of
myocytes after sham or AngII
treatment, as indicated. The
mean myocyte area was
evaluated by measurement of
150 cells per heart (n = 3 hearts
per group). (mean ± SEM.
*p\ 0.05). d Expression of
hypertrophy marker genes (a-
actin, ANP and Rcan1) in
saline- and AngII-treated
groups. Expression was
normalized to mTBP and
mPGK1 expression.
(mean ± SEM; n = 8 for each
group, *p\ 0.05, **p\ 0.01)
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Ca21 transients in WT and TRPM4-deficient adult
ventricular myocytes
To further investigate the cellular effect of AngII, we
measured Ca2? transients in intact cardiomyocytes
during field stimulation (stimulation frequency 1 Hz).
Under basal conditions, Ca2? transients were identical
in WT and Trpm4-/- myocytes. Application of 1 lmol/
L AngII to WT myocytes had a very moderate effect
on the amplitude and the AUC of the Ca2? transients.
However, Trpm4-/- cells displayed a more pronounced
response upon AngII application (Fig. 5a, b). Analyz-
ing the individual Ca2? transients during AngII appli-
cation, the increase of the peak values in WT and
Trpm4-/- myocytes was 4.8 ± 0.9 and 18.1 ± 5.1 %,
respectively (n = 15–17 for each group, p\ 0.05).
Similar differences were found when analyzing the area
under curve (AUC) of transients: the mean AngII-in-
duced increase was 0.9 ± 0.6 % in WT and
13.6 ± 3.8 % in Trpm4-/- myocytes (n = 15–17 for
each group, p\ 0.05). However, the time constant of
the decaying phase was not different between geno-
types, suggesting that the Ca2? extrusion mechanisms
are unchanged in the Trpm4-/- myocytes (Fig. 5c).
Increased store-operated Ca21 entry in Trpm42/2
adult ventricular myocytes
>Recent studies demonstrated that store-operated Ca2?
entry (SOCE) plays a key role in mediating cardiomyocyte
hypertrophy, both in vitro and in vivo [15, 16, 30, 32, 33].
To test whether the different effect of AngII on the global
Ca2? transients can be explained by differences in SOCE
between WT and Trpm4-/- adult ventricular myocytes, we
performed a Ca2? re-addition protocol, using AngII to
deplete the IP3 sensitive stores and thapsigargin to block
Ca2? reuptake by SERCA activity. Cells were kept in
nominally Ca2?-free solution in the presence of 1 lmol/L
AngII and 5 lmol/L thapsigargin for 5 min and subse-
quently perfused with a solution containing 2.5 mmol/L
Ca2? to allow SOCE. In these experiments, 30 % of the
WT and 65 % of the Trpm4-/- myocytes displayed an
increase in [Ca2?]i after Ca
2? re-addition. The average
fluorescent signals from WT and Trpm4-/- myocytes
during Ca2? re-addition is shown in Fig. 6a. Analyzing
[Ca2?]i during the Ca
2? re-addition, we found a signifi-
cantly higher increase in the AUC in Trpm4-/- myocytes
compared to WT (Fig. 6b). This indicates that AngII-me-
diated SOCE is increased in Trpm4-/- myocytes.
Fig. 4 Increased Trpm4-/-
myocyte hypertrophy in vitro.
a Representative TRPM4-
specific Western blotting from
neonatal hearts of WT and
Trpm4-/- mice. b Cell size of
WT and Trpm4-/- neonatal
cardiac myocytes before and
after 2 days of AngII (1 lmol/
L) treatment. (mean ± SEM;
*p\ 0.05, **p\ 0.01). 50–70
cells were counted from three
independent isolations per
group
43 Page 6 of 14 Basic Res Cardiol (2015) 110:43
123
Lack of membrane depolarization in Trpm42/2
adult ventricular myocytes during store depletion
Based on our SOCE experiments, we hypothesized that
during AngII application, the release of Ca2? from IP3-
sensitive stores can activate TRPM4, and the depolarizing
current via the channel can reduce the driving force for
Ca2? entry via SOCE channels, similar to the case in mast
cells [37]. This hypothesis also suggests that TRPM4
activation during the store depletion might lead to mod-
erate depolarization of the resting membrane potential. To
test this, we performed membrane potential measurement
during the above-discussed Ca2? re-addition protocol,
using the perforated patch technique (Fig. 6c). In WT
myocytes, we observed a significant 7.3 mV membrane
depolarization during the store depletion. In contrast, no
significant depolarization was measured in Trpm4-/-
myocytes (Fig. 6d) (WT: n = 13; Trpm4-/-: n = 14,
p\ 0.001). In these experiments, we never observed
depolarization beyond -60 mV, allowing us to exclude a
significant contribution of L-type Ca2? channel activity to
the [Ca2?]i increase during Ca
2?-reapplication. Further-
more, application of the L-type Ca2? channel blocker
nifedipine (1 lmol/L) had no effect on the [Ca2?]i
increase in Ca2? re-addition experiments (Supplementary
Figure 5). Application of 30 mmol/L K? at the end of the
Fig. 5 Ca2? transients during
AngII application in isolated
myocytes. a Representative
time course of Ca2? transients
from paced (1 Hz) WT and
Trpm4-/- ventricular myocytes.
b Overlay of representative
single traces of Ca2? transients
from WT and Trpm4-/-
myocytes in the presence (blue)
or absence (black) of AngII
(1 lmol/L). c Comparison of
the ratio of the peak value and
the AUC of the Ca2? transients
under basal and AngII-treated
conditions (left and middle
panel). Time constant of a
mono-exponential fit of the
decaying phase of the Ca2?
transients during AngII
application (right panel).
(mean ± SEM; n = 15–17
from 3 different isolations for
each group, *p\ 0.05)
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experiment depolarized the membrane potential and
induced a Ca2? transient, indicating that the myocytes are
intact and able to maintain their resting membrane
potential.
To test whether the difference in [Ca2?]i increase after
Ca2? re-addition between WT and Trpm4-/- myocytes is
mediated by a TRPM4-dependent membrane depolariza-
tion, we performed the Ca2? re-addition experiment while
Fig. 6 Increased store-operated calcium entry in Trpm4-/- myocytes
compared to WT. a Fluorescence recording of Ca2? entry in WT and
Trpm4-/- myocytes. The full black and red lines represent the mean
fluorescent values from WT and Trpm4-/- myocytes, respectively
(WT: n = 15, Trpm4-/-: n = 16 myocytes were isolated from 3
animals for each group). The dotted lines represent the corresponding
SEM values. Solutions were applied as indicated. b Comparison of
the AUC of fluorescent signal during the Ca2? re-addition phase in
panel (a). c Representative examples of a typical Ca2? re-addition
experiment, using extracellular solutions as in panel (a). At the end of
the experiment 30 mM K? was applied, to test the viability of the
cell. Intracellular Ca2? (red line) and membrane potential (black line)
were measured simultaneously. d Membrane potential of WT and
Trpm4-/- myocytes from an experiment as in panel (c), at the start of
thapsigargin and AngII application (full colored bar) and at the
maximal Ca2? level after Ca2? re-addition (patterned bar) (WT:
n = 13, Trpm4-/-: n = 14 myocytes were isolated from 4 animals
for each group). e Comparison of intracellular Ca2? level during Ca2?
re-addition, when the membrane potential of the myocytes is clamped
at -75 mV (WT: n = 8, Trpm4-/-: n = 9) (mean ± SEM in all
panels; *p\ 0.05; ***p\ 0.001, myocytes were isolated from 3
animals for each group)
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clamping the membrane potential at -75 mV. Under this
condition, we no longer observed a difference in the rise in
[Ca2?]i between WT and Trpm4
-/- myocytes during the
Ca2? re-addition phase (Fig. 6e).
Increased calcineurin phosphatase activity in hearts
of Trpm4cKO
To further investigate the mechanisms behind the altered
hypertrophic response in Trpm4cKO mice, calcineurin
enzyme activity was measured. Previously, we have seen
increased expression of Rcan1, an endogenous reporter of
calcineurin–NFAT activity, in AngII-treated Trpm4cKO
animals (Fig. 3d), which is most likely the result of the
enhanced activation of calcineurin [42]. It has been shown
previously that the calcium-activated phosphatase cal-
cineurin is both necessary and sufficient to induce cardiac
hypertrophy and that both its protein expression and
phosphatase activity are increased in response to hyper-
trophic stimuli [28, 35]. To test calcineurin activity
directly, we performed a calcineurin enzyme activity assay.
We observed a significant increase in calcineurin activity in
the hearts of AngII-treated animals and this increase was
even higher in Trpm4cKO animals (n = 10 for each group,
p\ 0.05) (Fig. 7a). However in sham-treated animals,
total phosphatase activity was not significantly different
between WT and Trpm4cKO samples (Supplementary Fig-
ure 6). To further investigate calcineurin activity, we per-
formed calcineurin-specific Western blot analysis on the
same hearts. In line with the increased phosphatase activ-
ity, we observed *1.6 times more protein in WT AngII-
treated and *2.4 times more in Trpm4cKO AngII-treated
animals, whereas there was no significant difference in
calcineurin protein level between the genotypes after sham
treatment (Fig. 7b). These results suggest that higher
SOCE in AngII-treated Trpm4cKO myocytes leads to an
enhanced calcineurin signaling and to a stronger hyper-
trophic response.
Discussion
In this study, we demonstrated the effect of the calcium-
activated non-selective cation channel TRPM4 on the
development of cardiac hypertrophy upon chronic AngII
infusion. In our experiments, mice lacking the channel
exclusively in the heart were more sensitive to hyper-
trophic stimulus than WT mice. They displayed a signifi-
cantly increased heart mass and myocyte cross-sectional
area after 2 weeks of chronic AngII treatment. Further-
more, they showed a stronger re-activation of the fetal gene
program than WT-treated mice. The increased sensitivity
to AngII treatment was also present in vitro in cultured
neonatal cardiac myocytes. Finally, we provide evidence
that the increased response to AngII treatment was due to
the lack of a TRPM4-dependent membrane depolarization
leading to increased Ca2? influx via store-operated Ca2?
channels. The increased Ca2? influx most likely explains
the enhanced activation of the calcineurin–NFAT pathway
in Trpm4cKO myocytes.
AngII is considered as a hypertrophic agent on myocytes
since the first description on embryonic chicken cells [1]
and later on other species. AngII not only increases blood
pressure, through its constrictive effect on the vasculature,
but also promotes growth and hypertrophy of cardiac tissue
independent of hypertension through the Ang II receptor
Fig. 7 Increased calcineurin
enzyme activity in Trpm4cKO
cardiac muscle compared to WT
upon AngII treatment.
a Calcineurin phosphatase
activity, measured from cardiac
muscle tissue lysates from WT
and Trpm4cKO mice, after sham
or AngII treatment, as indicated
(mean ± SEM; n = 10 for each
group, *p\ 0.05).
b Representative calcineurin-
specific Western blotting from
cardiac muscle lysates of WT
and Trpm4cKO mice, after sham
or AngII treatment, as indicated.
Lysates from three hearts per
group were pooled in each lane
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type 1 (AT1R), which is expressed in cardiomyocytes [27,
38]. Activation of the AT1 receptor triggers a Gq-coupled
cascade that results in the formation of IP3 and DAG. IP3
subsequently stimulates the release of Ca2? from intracel-
lular IP3-sensitive Ca
2? stores. It has been shown that IP3-
mediated Ca2? release plays a central role in regulating
cardiomyocyte hypertrophy induced by different stimuli,
including AngII infusion [29]. On the other hand, apart from
Ca2? release, AngII receptor activation will also induce
Ca2? influx, via store-operated Ca2? channels, which might
involve TRPC channels [10, 33] and/or STIM/ORAI
channel complexes [15, 32]. It is increasingly recognized
that SOCE is present in cardiomyocytes and serves as an
important mechanism in hypertrophy signaling [4]. The
presence of SOCE on myocytes has been shown already
many years ago [16]. Several publications demonstrated
that upon store depletion, SOCE facilitates the influx of
Ca2? from the extracellular space to refill intracellular
stores, while the resulting increase in intracellular Ca2?
concentration also regulates hypertrophy pathways, such as
the calcineurin/NFAT cascade [15, 30, 32, 41].
TRPM4 has been described as a regulator of Ca2? influx
and Ca2?-dependent cell functions in many cell types,
including ventricular cardiac myocytes [24, 25, 37]. We have
previously shown that TRPM4 proteins are determinants of
the inotropic effects of b-adrenergic stimulation by modulat-
ing ICaL activity. Moreover, it has been shown that in mast
cells TRPM4 is a regulator of Ca2? influx via SOCE channels
upon depletion of intracellular Ca2? stores. Since SOCEplays
a key role in cardiomyocyte hypertrophy, and TRPM4 is
functionally present in mouse ventricular myocytes, we
hypothesized that TRPM4 might also regulate the driving
force for Ca2? entry during hypertrophic stimulus and there-
fore could regulate cardiomyocyte hypertrophy signaling.
One major pitfall in research dealing with TRPM4 physi-
ology is the lack of specific inhibitors. 9-Phenantrol has
received a lot of attention recently as a TRPM4antagonist, but
it has to bementioned that the selectivity of this compound on
TRPM4 is doubtful. It has been shown recently that 9-phe-
nantrol also activates calcium-activated potassium channels
and blocks calcium-activated chloride channels, which limits
its usefulness in experiments using primary cells and living
animals [2, 11]. To investigate our hypothesis, we generated
cardiac-specific Trpm4-/- mice (Trpm4cKO). Notably, Trp-
m4cKO mice do not display hypertension, as was described
previously in globalTrpm4-/-mice [25].Using theTrpm4cKO
line, we observed increased heart size after 2 weeks of AngII
infusion and also increased myocyte size in histological sec-
tions compared to WT. No differences were observed in the
saline-treated groups. It was described recently that the global
Trpm4-/- mice display increased HW/BW ratios even with-
out hypertrophic treatment as a result of hyperplasia, but we
did not observe this in cardiac-specific Trpm4cKO mice [6].
Masson trichrome staining showed increased fibrosis after
AngII treatment, but this was not different between WT and
Trpm4cKO, suggesting that the fibroblast function is not altered
by the TRPM4 deletion. We have also found significant
increases in the expression levels of several hypertrophy-re-
lated genes after AngII treatment in both genotypes, and in
case ofa-actin,ANPandRcan1 this increasewas significantly
higher inTrpm4cKOmice. ANP and a-actin are commonly up-
regulated in case of cardiac hypertrophy; however, Rcan1 is a
reporter of calcineurin–NFAT activation, a well described
pathway in cardiac hypertrophy. Since the first description in
myocytes, this pathway has been shown several times to be
necessary and sufficient for the induction of cardiac hyper-
trophy [28].
Another profound change in Trpm4-/- myocytes was the
altered Ca2? handling during AngII application. As shown
before, application ofAngII to adult ventricular myocytes had
very little effect on calcium transients in case ofWTmyocytes
[18]. However, Trpm4-/- myocytes responded to AngII
application with a significant increase in terms of the ampli-
tude and the AUC of the Ca2? transients. This observation
suggests thatTRPM4deletion has an effect onAngII receptor-
mediated [Ca2?]i elevation. In our previous work, we per-
formed awhole-genomemRNA transcript analysis inWTand
Trpm4-/- heart tissue where we found now major up- or
downregulation of any genes involved in AngII receptor sig-
naling [24]. However, it has been shown that AngII applica-
tion can also induce [Ca2?]i elevation via SOCE channels
[30]. Considering that TRPM4 regulates the driving force for
SOCE in other cell types, we performed Ca2? re-addition
experiments as described earlier [16] to assess directly the
magnitude of SOCE in WT and Trpm4-/- myocytes. We
observed increased [Ca2?]i in Trpm4
-/-myocytes after store
depletion by AngII compared to WT cells, which is in line
with previous observations in mast cells [37]. As was pub-
lishedbefore, not everymyocyte displaysSOCE in this typeof
assay. The ratio of responding/non-responding myocytes in
WTwas in line with previously published data. However, the
number of responding myocytes was significantly higher in
Trpm4-/-mice and is similar to the response rate ofmyocytes
from hypertrophied hearts [17, 41].
Why do Trpm4-/- myocytes display increased store-op-
erated Ca2? influx during AngII application? It is well
known that TRPM4 activation by high [Ca2?]i leads to an
inward current and the subsequent depolarization can limit
the driving force for calcium ions via voltage and non-volt-
age-gated calcium channels. This has been shown in differ-
ent cell types including mast cells and cardiac myocytes [24,
37]. Furthermore, Earley and coworkers showed that release
of Ca2? from IP3-sensitive internal stores can specifically
activate TRPM4 and generate a sustained inward current in
cerebral smooth muscle cells [12]. Taken together, our data
are consistent with the hypothesis that AngII application in
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cardiac myocytes leads to Ca2? release from IP3-sensitive
stores, which activates TRPM4, concomitantly with opening
of SOCE channels (Supplementary Figure 7). The depolar-
izing TRPM4 current then limits the driving force for Ca2?
entry via the SOCE channels. Consistent with this, when we
clamped the membrane potential at -75 mV in myocytes
from both genotypes the differences in [Ca2?]i after Ca
2? re-
addition was no longer present, suggesting that the original
difference was mediated by a TRPM4-dependent membrane
depolarization.
Several recent studies showed that Ca2? entry through
SOCE channels can activate the calcineurin–NFAT pathway
and cause pathological cardiac hypertrophy [16, 30, 32, 41].
Calcineurin is a calcium-dependent phosphatase which,
upon activation, dephosphorylates NFAT and promotes its
translocation to the nucleus. The activated NFAT initiates
the expression of hypertrophy-related genes, including
Rcan1. Based on our model, we would expect increased
calcineurin–NFAT activation, in line with the observed
increased SOCE in Trpm4-/- myocytes. Indeed, in mRNA
expression experiments, we observed increased Rcan1
upregulation in Trpm4cKO hearts, which is an indicator of the
activation of calcineurin–NFAT pathway [42]. To study
calcineurin signaling in these hearts, we assessed cal-
cineurin-dependent phosphatase activity and calcineurin
expression. It was described previously that the amount of
calcineurin protein and subsequently phosphatase activity is
enhanced in response to hypertrophic stimuli [35]. Consis-
tent with this, we observed increased enzyme activity inWT
hearts treated with AngII, and this increase was more
prominent in Trpm4cKOmice.We observed similar results in
terms of the amount of protein, which was increased*1.6
times in WT and *2.5 times in Trpm4cKO animals after
AngII infusion. In sham-treated animals, no difference was
apparent between both genotypes.
Taken together, our data describe the role of TRPM4 in
the development of AngII-induced pathological cardiac
hypertrophy. TRPM4, as a Ca2?-activated non-selective
cation channel negatively modulates the intracellular Ca2?
signaling induced by AngII, by limiting the driving force for
Ca2? influx via SOCE channels. Therefore, it can fine-tune
the amount of calcium activating the calcineurin–NFAT
pathway, regulating pathological cardiac hypertrophy.
Materials and methods
Mice
To obtain cardiac-specific Trpm4 knockout mice, Trpm4L3F2
mice (see Fig. 1) were crossed with EIIa-Cre mice (obtained
from the Jackson Laboratory). From the offspring, Trpm4flox
mice were selected for further breeding. Subsequently,
Trpm4flox mice were crossed with MLC2a-Cre mice, which
resulted in cardiac-specific deletion of exon 15 and 16 of the
TRPM4 gene, which encode the first transmembrane domain
of the TRPM4 protein. Western blotting confirmed deletion
of the protein from the heart (see Fig. 1 in the main text).
Mice were routinely genotyped using PCR. For more details
on the targeting strategy, see [40]. Experiments were per-
formed on 3- to 6-month-oldmale C57BL/6 Nmice and age-
and sex-matched Trpm4-/- or cardiac-specific Trpm4
knockout (Trpm4cKO) mice. Mice were housed with a 12-h
light/12-h dark cycle and allowed water and standard food
ad libitum. All animal experiments were performed
according to the Guide for the Care and Use of Laboratory
Animals (8th edition, National Research Council, USA,
2011) and were approved by the local ethics committee. All
mention of Trpm4cKO in this paper refers to cardiac-specific
Trpm4 knockout mice.
Adult ventricular cardiomyocytes isolation
8- to 12-week-old mice were heparinized and killed by
intraperitoneal injection of pentobarbital (Nembutal,
CEVA). The hearts were removed and perfused retrograde
for 2 min through the aorta with a Langendorff apparatus at
37 C with oxygen-saturated nominally calcium-free solu-
tion containing (in mmol/L): 117 NaCl, 4 KCl, 1 KH2PO4, 4
NaHCO3, 1.7 MgCl2, 10 HEPES, and 10 glucose (pH 7.4).
This step was followed by 4–6 min of perfusion with
digestion solution [as above, but supplemented with 1 mg/
ml collagenase B (Worthington)]. Subsequently, the heart
was removed from the setup, atria were discarded and ven-
tricular muscle was minced in collagenase solution (see
above). The suspension was filtered through a nylon filter,
and cells were centrifuged at 5009g for 2 min. The super-
natant was discarded and the myocytes were resuspended in
the first solution, but supplemented with 1 mmol/L CaCl2.
Calcium-tolerant, rod-shaped myocytes with clear striations
were used for measurements on the day of the isolation.
Ca21 measurements
For imaging of intracellular Ca2? dynamics, isolated ven-
tricular myocytes were loaded with the Ca2? indicator
Fluo-4-AM (1 lmol/L) for 15 min at room temperature.
Cells were seeded on glass coverslips in extracellular
solution containing (in mmol/L): 118 NaCl, 4.7 KCl, 2.52
CaCl2, 1.64 MgSO4, 24.88 NaHCO3, 1.18 KH2PO4, 6
glucose, 2 Na pyruvate. This solution was continuously
bubbled with carbogen (5 % CO2, 95 % O2). Electrical
stimulation was achieved using field stimulation. Fluores-
cence was detected with a photo-multiplier tube and
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acquired by the Patchmaster software. Excitation light
(480 nm) was provided by a Polychrome V monochro-
mator (Till Photonics, Germany).
SOCE measurement
For store-operated calcium entry measurement, myocytes
were handled as above.Myocytes were treatedwith 1 lmol/L
AngII and 5 lmol/L thapsigargin for 5–6 min in nominally
Ca2?-free buffer to deplete SR stores. Myocytes were then
perfused with high Ca2? (2.5 mmol/L), in the continuous
presence of thapsigargin and AngII, and store-operated entry
was measured as an increase in Fluo-4 fluorescence. For the
measurement of the restingmembrane potential during SOCE
experiment, perforated patch technique was used in current
clamp mode. In these experiments the pipette solution con-
tained (in mmol/L) 10 KCl, 10 NaCl, 70 K2SO4, 1 MgCl2 10
Hepes and 240 lg/ml amphotericin B, pH 7.3.
Surgical modeling and physiological analysis
8- to 12-week-old mice were anesthetized with isoflurane.
Mini-osmotic pumps (Alzet, model: 1002) filled with
3 mg/kg/day Ang II (Calbiochem) or with saline were
implanted subcutaneously. Two weeks after the operation,
animals were killed by cervical dislocation, hearts were
removed, cleaned from fat tissue and big vessels, washed in
PBS and weighed. Subsequently, the left tibia was dis-
sected and the length of the bone was measured.
Isolation of neonatal cardiac myocytes
Neonatal mice (1- to 2-day-old) were used for isolation.
Hearts were removed aseptically; atria and big vessels were
discarded. The ventricles were cut into small pieces and
digested in 0.25 % trypsin for 15 min at 37 C. Subse-
quently, supernatants were removed and mixed with an
equal volume of HBSS with Ca2? and Mg2?. This step was
repeated four to five times until the hearts were completely
digested. The cells were then cultured in DMEM supple-
mented with 20 % FBS for 2–3 h, allowing the attachment
of non-myocytes. Later, the cells in the supernatant were
used and cultured in DMEM supplemented with 20 %
FBS. After 1 day, the medium was changed to DMEM
without FBS and supplemented with 1 lM AngII for 48 h.
Calcineurin phosphatase activity assay
Tissue samples from freshly isolated hearts of WT and
Trpm4cKO mice were lysed in calcineurin assay buffer
(Enzo Life Science) and centrifuged at 20009g. The
supernatant was then snap frozen at -70 C. The phos-
phatase activity assay (BML-AK816) was performed based
on the manufacturer’s instruction (Enzo Life Science).
Calcineurin phosphatase activity was measured spec-
trophotometrically by detecting free phosphate released
from the calcineurin-specific RII phosphopeptide.
Western blot analysis
Proteins from freshly isolated heart of wild-type and Trp-
m4cKO mice were lysed in 1 ml ice-cold lysis buffer
(100 mmol/L Tris–HCl, 1 mmol/L MgCl2, 0.1 mmol/L
phenylmethylsulfonyl fluoride [PMSF] [pH 8] and a pro-
tease inhibitors cocktail (ProteoguardTM Clontech) using a
Polytron homogenizer. Subsequently, 4 ml saccharose
buffer (250 mmol/L saccharose, 10 mmol/L Tris–HCl [pH
7.4], 0.1 mmol/L PMSF and protease inhibitor cocktail)
was added to the lysate. The obtained homogenates were
centrifuged at 30009g for 15 min to remove any remaining
large cellular fragments. The supernatants were ultracen-
trifuged at 200,0009g for 30 min. Pellets containing total
membrane fractions were solubilized in a cold saccharose
buffer. Protein concentrations were determined by the
bicinchoninic acid assay method, using bovine serum
albumin (BSA) as a standard. Samples (80 lg) were sub-
jected to SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and subsequently transferred to a polyvinylidene
fluoride (PVDF) membrane (Bio-Rad, USA). The respec-
tive proteins were detected with purified rabbit polyclonal
antibody (Ak578) directed against the amino-terminal end
of mouse TRPM4 (27), isoform-specific mouse monoclonal
calcineurin-Aß (sc365612; Santa Cruz Biotechnology) and
monoclonal mouse anti-Na?/K? ATPase (1: 5000 dilution)
(Abcam, UK) antibodies. Immunoreactive complexes were
visualized by chemiluminescence, using anti-rabbit IgG
(Sigma, USA) or anti-mouse IgG (GE Healthcare) anti-
bodies conjugated to horseradish peroxidase.
Histology
Four mice of each genotype were perfused with saline.
Then the hearts were fixed with zinc-based fixative solution
(BD Pharmingen, USA). Subsequently, hearts were pro-
cessed and embedded in paraffin wax. Serial sections were
cut to a thickness of 5–7 lm and documented using a Zeiss
microscope (Axiovert 40). For Masson’s trichrome stain-
ing, a commercially available kit (Sigma-Aldrich) was used
based on the supplier’s instructions. For the analysis of the
obtained pictures, ImageJ (NIH, USA) software was used.
Analysis of gene expression
After euthanasia by cervical dislocation, hearts were
removed, washed in ice-cold PBS, immediately snap fro-
zen in liquid nitrogen and kept at -80 C until final
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processing. Total RNA was extracted using the RNeasy
Mini Kit (Qiagen), following the manufacturer’s protocol.
RNA concentration and quality were assessed using the
Experion RNA StdSens Analysis Kit (Bio-Rad). For cDNA
synthesis, Ready-To-Go You-Prime First-Strand Beads
(GE Healthcare) were used based on the supplier’s proto-
col. Generated cDNAs were stored at -20 C. qPCR
reactions, composed of cDNA template, Universal Taq-
Man MasterMix (29 concentrated, Life Technologies),
TaqMan assay (209 concentrated, Life Technologies) and
H2O, were performed with the 7500 Fast Real-Time PCR
System (Life Technologies). mPGK1 and mTBP, selected
using the geNorm application, were used as endogenous





All statistical analyses were performed using Prism
(Graphpad) or Origin (Microcal, USA) software. Data are
expressed as mean ± SEM, unless otherwise specified.
Differences between groups were compared by two-sample
t test and two-way repeated measurement ANOVA followed
by a Tukey post hoc test, unless mentioned otherwise. When
assumptions were not valid, non-parametric tests were per-
formed (Mann–Whitney test, FriedmanANOVA). A p value
\0.05 was considered to be statistically significant.
Acknowledgments We wish to thank all members of the Labora-
tory of Ion Channel Research for helpful discussions. The authors
have no competing financial interests in relation to this work. This
work was supported by FWO Vlaandren (G.0761.10 N, ASP/11-Griet
Jacobs, G.0596.12, G.0565.07), IUAP program from the Belgian
Federal Government (IcePath, P7/13), KULeuven ‘‘Bijzonder
Onderzoeksfonds’’ (STRT1/09/046, GOA 2009/07, EF/95/010 and
TRPLe), the Klinische Forschergruppe 196 (Signaltransduktion bei
adaptativen und maladaptativen kardialen Remodeling-Prozessen;
MF, VF), SFB 894 (VF) and the DZHK (German Centre for Car-
diovascular Research) and the BMBF (German Ministry of Education
and Research; MF).
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Baker KM, Aceto JF (1990) Angiotensin II stimulation of protein
synthesis and cell growth in chick heart cells. Am J Physiol
259:H610–H618
2. Burris SK, Wang Q, Bulley S, Neeb ZP, Jaggar JH (2015)
9-phenanthrol inhibits recombinant and arterial myocyte
TMEM16A channels. Br J Pharmacol. doi:10.1111/bph.13077
3. Chiang CS, Huang CH, Chieng H, Chang YT, Chang D, Chen JJ,
Chen YC, Chen YH, Shin HS, Campbell KP, Chen CC (2009)
The Ca(v)3.2 T-type Ca(2?) channel is required for pressure
overload-induced cardiac hypertrophy in mice. Circ Res
104:522–530. doi:10.1161/CIRCRESAHA.108.184051
4. Collins HE, Zhu-Mauldin X, Marchase RB, Chatham JC (2013)
STIM1/Orai1-mediated SOCE: current perspectives and potential
roles in cardiac function and pathology. Am J Physiol Heart Circ
Physiol 305:H446–H458. doi:10.1152/ajpheart.00104.2013
5. Demion M, Bois P, Launay P, Guinamard R (2007) TRPM4, a
Ca2?-activated nonselective cation channel in mouse sino-atrial
node cells. Cardiovasc Res 73:531–538. doi:10.1016/j.cardiores.
2006.11.023
6. Demion M, Thireau J, Gueffier M, Finan A, Khoueiry Z, Cassan
C, Serafini N, Aimond F, Granier M, Pasquie JL, Launay P,
Richard S (2014) Trpm4 gene invalidation leads to cardiac
hypertrophy and electrophysiological alterations. PLoS One
9:e115256. doi:10.1371/journal.pone.0115256
7. Fonfria E, Murdock PR, Cusdin FS, Benham CD, Kelsell RE,
McNulty S (2006) Tissue distribution profiles of the human
TRPM cation channel family. J Recept Signal Transduct Res
26:159–178. doi:10.1080/10799890600637506
8. Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the
heart: a new therapeutic target? Circulation 109:1580–1589.
doi:10.1161/01.CIR.0000120390.68287.BB
9. Frey N, Olson EN (2003) Cardiac hypertrophy: the good, the bad,
and the ugly. Annu Rev Physiol 65:45–79. doi:10.1146/annurev.
physiol.65.092101.142243
10. Gao H, Wang F, Wang W, Makarewich CA, Zhang H, Kubo H,
Berretta RM, Barr LA, Molkentin JD, Houser SR (2012) Ca(2?)
influx through L-type Ca(2?) channels and transient receptor
potential channels activates pathological hypertrophy signaling.
J Mol Cell Cardiol 53:657–667. doi:10.1016/j.yjmcc.2012.08.005
11. Garland CJ, Smirnov SV, Bagher P, Lim CS, Huang CY, Mitchell
R, Stanley C, Pinkney A, Dora KA (2014) TRPM4 inhibitor
9-phenanthrol activates endothelial cell intermediate conductance
calcium-activated potassium channels in rat isolated mesenteric
artery. Br J Pharmacol. doi:10.1111/bph.12985
12. Gonzales AL, Amberg GC, Earley S (2010) Ca2? release from
the sarcoplasmic reticulum is required for sustained TRPM4
activity in cerebral artery smooth muscle cells. Am J Physiol Cell
Physiol 299:C279–C288. doi:10.1152/ajpcell.00550.2009
13. Guinamard R, Bois P (2007) Involvement of transient receptor
potential proteins in cardiac hypertrophy. Biochim Biophys Acta
1772:885–894. doi:10.1016/j.bbadis.2007.02.007
14. Heineke J, Molkentin JD (2006) Regulation of cardiac hyper-
trophy by intracellular signalling pathways. Nat Rev Mol Cell
Biol 7:589–600. doi:10.1038/nrm1983
15. Hulot JS, Fauconnier J, Ramanujam D, Chaanine A, Aubart F,
Sassi Y, Merkle S, Cazorla O, Ouille A, Dupuis M, Hadri L,
Jeong D, Muhlstedt S, Schmitt J, Braun A, Benard L, Saliba Y,
Laggerbauer B, Nieswandt B, Lacampagne A, Hajjar RJ, Lompre
AM, Engelhardt S (2011) Critical role for stromal interaction
molecule 1 in cardiac hypertrophy. Circulation 124:796–805.
doi:10.1161/CIRCULATIONAHA.111.031229
16. Hunton DL, Lucchesi PA, Pang Y, Cheng X, Dell’Italia LJ,
Marchase RB (2002) Capacitative calcium entry contributes to
nuclear factor of activated T-cells nuclear translocation and
hypertrophy in cardiomyocytes. J Biol Chem 277:14266–14273.
doi:10.1074/jbc.M107167200
17. Hunton DL, Zou L, Pang Y, Marchase RB (2004) Adult rat
cardiomyocytes exhibit capacitative calcium entry. Am J Physiol
Basic Res Cardiol (2015) 110:43 Page 13 of 14 43
123
Heart Circ Physiol 286:H1124–H1132. doi:10.1152/ajpheart.
00162.2003
18. Ikenouchi H, Barry WH, Bridge JH, Weinberg EO, Apstein CS,
Lorell BH (1994) Effects of angiotensin II on intracellular Ca2?
and pH in isolated beating rabbit hearts and myocytes loaded with
the indicator indo-1. J Physiol 480(Pt 2):203–215
19. Inoue R, Jensen LJ, Shi J, Morita H, Nishida M, Honda A, Ito Y
(2006) Transient receptor potential channels in cardiovascular
function and disease. Circ Res 99:119–131. doi:10.1161/01.RES.
0000233356.10630.8a
20. Jacobs G, Oosterlinck W, Dresselaers T, Geenens R, Kerselaers
S, Himmelreich U, Herijgers P, Vennekens R (2015) Enhanced
beta-adrenergic cardiac reserve in Trpm4-/- mice with ischae-
mic heart failure. Cardiovasc Res. doi:10.1093/cvr/cvv009
21. Kruse M, Schulze-Bahr E, Corfield V, Beckmann A, Stallmeyer
B, Kurtbay G, Ohmert I, Brink P, Pongs O (2009) Impaired
endocytosis of the ion channel TRPM4 is associated with human
progressive familial heart block type I. J Clin Invest
119:2737–2744. doi:10.1172/JCI38292
22. Launay P, Fleig A, Perraud AL, Scharenberg AM, Penner R,
Kinet JP (2002) TRPM4 is a Ca2?-activated nonselective cation
channel mediating cell membrane depolarization. Cell
109:397–407 (pii: S0092867402007195)
23. Makarewich CA, Correll RN, Gao H, Zhang H, Yang B, Berretta
RM, Rizzo V, Molkentin JD, Houser SR (2012) A caveolae-
targeted L-type Ca2? channel antagonist inhibits hypertrophic
signaling without reducing cardiac contractility. Circ Res
110:669–674. doi:10.1161/CIRCRESAHA.111.264028
24. Mathar I, Kecskes M, Van der Mieren G, Jacobs G, Camacho
Londono JE, Uhl S, Flockerzi V, Voets T, Freichel M, Nilius B,
Herijgers P, Vennekens R (2014) Increased beta-adrenergic ino-
tropy in ventricular myocardium from Trpm4-/- mice. Circ Res
114:283–294. doi:10.1161/CIRCRESAHA.114.302835
25. Mathar I, Vennekens R, Meissner M, Kees F, Van der Mieren G,
Camacho Londono JE, Uhl S, Voets T, Hummel B, van den
Bergh A, Herijgers P, Nilius B, Flockerzi V, Schweda F, Freichel
M (2010) Increased catecholamine secretion contributes to
hypertension in TRPM4-deficient mice. J Clin Invest
120:3267–3279. doi:10.1172/JCI41348
26. Mills RW, Milan DJ (2010) TRPM4-linked isolated cardiac
conduction defects: bad trafficking causes electrical gridlock.
Circ Cardiovasc Genet 3:311–313. doi:10.1161/CIRCGE
NETICS.110.957670
27. Miyata S, Haneda T (1994) Hypertrophic growth of cultured
neonatal rat heart cells mediated by type 1 angiotensin II recep-
tor. Am J Physiol 266:H2443–H2451
28. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J,
Robbins J, Grant SR, Olson EN (1998) A calcineurin-dependent
transcriptional pathway for cardiac hypertrophy. Cell 93:215–228
(pii: S0092-8674(00)81573-1)
29. Nakayama H, Bodi I, Maillet M, DeSantiago J, Domeier TL,
Mikoshiba K, Lorenz JN, Blatter LA, Bers DM, Molkentin JD
(2010) The IP3 receptor regulates cardiac hypertrophy in
response to select stimuli. Circ Res 107:659–666. doi:10.1161/
CIRCRESAHA.110.220038
30. Nakayama H, Wilkin BJ, Bodi I, Molkentin JD (2006) Cal-
cineurin-dependent cardiomyopathy is activated by TRPC in the
adult mouse heart. FASEB J 20:1660–1670. doi:10.1096/fj.05-
5560com
31. Nilius B, Vennekens R (2006) From cardiac cation channels to
the molecular dissection of the transient receptor potential
channel TRPM4. Pflugers Arch 453:313–321. doi:10.1007/
s00424-006-0088-z
32. Ohba T, Watanabe H, Murakami M, Sato T, Ono K, Ito H (2009)
Essential role of STIM1 in the development of cardiomyocyte
hypertrophy. Biochem Biophys Res Commun 389:172–176.
doi:10.1016/j.bbrc.2009.08.117
33. Onohara N, Nishida M, Inoue R, Kobayashi H, Sumimoto H, Sato
Y, Mori Y, Nagao T, Kurose H (2006) TRPC3 and TRPC6 are
essential for angiotensin II-induced cardiac hypertrophy. EMBO J
25:5305–5316. doi:10.1038/sj.emboj.7601417
34. Stallmeyer B, Zumhagen S, Denjoy I, Duthoit G, Hebert JL,
Ferrer X, Maugenre S, Schmitz W, Kirchhefer U, Schulze-Bahr
E, Guicheney P (2012) Mutational spectrum in the Ca(2?)—
activated cation channel gene TRPM4 in patients with cardiac
conductance disturbances. Hum Mutat 33:109–117. doi:10.1002/
humu.21599
35. Taigen T, De Windt LJ, Lim HW, Molkentin JD (2000) Targeted
inhibition of calcineurin prevents agonist-induced cardiomyocyte
hypertrophy. Proc Natl Acad Sci USA 97:1196–1201
36. Uhl S, Mathar I, Vennekens R, Freichel M (2014) Adenylyl
cyclase-mediated effects contribute to increased Isoprenaline-in-
duced cardiac contractility in TRPM4-deficient mice. J Mol Cell
Cardiol 74:307–317. doi:10.1016/j.yjmcc.2014.06.007
37. Vennekens R, Olausson J, Meissner M, Bloch W, Mathar I,
Philipp SE, Schmitz F, Weissgerber P, Nilius B, Flockerzi V,
Freichel M (2007) Increased IgE-dependent mast cell activation
and anaphylactic responses in mice lacking the calcium-activated
nonselective cation channel TRPM4. Nat Immunol 8:312–320.
doi:10.1038/ni1441
38. Wada H, Zile MR, Ivester CT, Cooper G, McDermott PJ (1996)
Comparative effects of contraction and angiotensin II on growth
of adult feline cardiocytes in primary culture. Am J Physiol
271:H29–H37
39. Watanabe H, Murakami M, Ohba T, Takahashi Y, Ito H (2008)
TRP channel and cardiovascular disease. Pharmacol Ther
118:337–351. doi:10.1016/j.pharmthera.2008.03.008
40. Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie TM,
Chen J, Chien KR, Offermanns S (2001) Absence of pressure
overload induced myocardial hypertrophy after conditional
inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med
7:1236–1240. doi:10.1038/nm1101-1236
41. Wu X, Eder P, Chang B, Molkentin JD (2010) TRPC channels
are necessary mediators of pathologic cardiac hypertrophy. Proc
Natl Acad Sci USA 107:7000–7005. doi:10.1073/pnas.
1001825107
42. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson
EN, Bassel-Duby R, Williams RS (2000) Independent signals
control expression of the calcineurin inhibitory proteins MCIP1
and MCIP2 in striated muscles. Circ Res 87:E61–E68
43 Page 14 of 14 Basic Res Cardiol (2015) 110:43
123
